Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases.

Journal article

Tumor necrosis factor-alpha (TNF) has been unequivocally validated as a therapeutic target in a number of immune-mediated inflammatory disorders (IMIDs). There is now increasing choice of biologic agents within the class all of which successfully neutralize sTNF. But approaches to TNF inhibition differ and currently include mAbs (infliximab, adalimumab, and golimumab), either chimeric or human in sequence, a PEGylated Fab' fragment (certolizumab), and an IgG1-TNFR2 fusion protein (etanercept)...

Expand abstract

Authors: Taylor, P

• Publication status: Published
• Journal: Current opinion in pharmacology
• Volume: 10
• Issue: 3
• Pages: 308-315
• Publication date: 2010-06-01
• DOI: 10.1016/j.coph.2010.01.005
• EISSN: 1471-4973
• ISSN: 1471-4892
• Language: English
• Keywords: Drug Delivery Systems; Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Inflammation; Antibodies, Monoclonal; Humans; Arthritis, Rheumatoid; Immunologic Factors; Tumor Necrosis Factor-alpha; Chronic Disease